Menu Search
Equities

Kalekim Kimyevi Maddeler Sanayi ve Ticaret AS

KLKIM.E:IST

Kalekim Kimyevi Maddeler Sanayi ve Ticaret AS

Actions
IndustrialsGeneral Industrials
  • Price (TRY)32.80
  • Today's Change1.50 / 4.79%
  • Shares traded7.05m
  • 1 Year change+25.10%
  • Beta0.8428
Data delayed at least 15 minutes, as of Nov 08 2024 15:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Share price forecast

The one analyst offering a 12 month price target expects Kalekim Kimyevi Maddeler Sani ve Tit AS share price to fall to 26.26 in the next year from the last price of 32.80.
High-19.9%26.26
Med-19.9%26.26
Low-19.9%26.26

Earnings history & estimates in TRY

Annual earnings information is not available for Kalekim Kimyevi Maddeler Sani ve Tit AS.
More ▼

Revenue history & estimates in TRY

of 724.50m. This bettered the 633.00m estimate of the one analyst covering the company. The same period last year the company did not report revenues.
Average growth rate+15.07%
Kalekim Kimyevi Maddeler Sani ve Tit AS had revenues for the full year 2023 of 4.67bn. This was 117.80% above the prior year's results.
Average growth rate+117.80%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.